Alternatives to TIXiMED
TIXiMED is a Biotechnology tool: clinical-stage pharmaceutical company developing innovative oral therapies for diabetes and metabolic disorders. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
The 20 closest Biotechnology companies to TIXiMED
- Website
Mironid59BiotechnologyGlasgow, United Kingdom$46.0MBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Website
Verdiva Bio54BiotechnologySan Diego, United States$170.0MClinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.
- Website
Ray Therapeutics53BiotechnologyBerkeley, USA$243.0MPioneering vision restoration therapies for severe retinal degenerations.
- Website COContraline48BiotechnologyCharlottesville, USA$102.5M
Developing novel male contraceptives.
- Website
Turn Therapeutics38BiotechnologyLos Angeles, USA$25.0MA clinical-stage dermatology company developing novel therapies for inflammatory skin diseases.
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- JUJuno Therapeutics66BiotechnologySeattle, United States$316.7M
Biotechnology company focused on developing cancer immunotherapies.
- Website
Kite Pharma66BiotechnologySanta Monica, United States$421.2MBiotechnology company developing and commercializing cell therapies for cancer treatment.
- Website
CRISPR Therapeutics64BiotechnologyZug, Switzerland$547.0MBiotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
- NANanoPhoria23BiotechnologyItaly$83.5M
Developing inhalable therapies for cardiovascular diseases using a proprietary nanoparticle platform.
- Website
Degron Therapeutics62BiotechnologySan Diego, USA$40.0MClinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
- Website
Seaport Therapeutics62BiotechnologyCambridge, USA$340.0MDeveloping novel therapeutics to restore gut lymphatic function.
- Website
Alcolase85BiotechnologyCopenhagen, DenmarkEnzyme-based technology to break down alcohol in the stomach.
- Website
Adcendo60BiotechnologyCopenhagen, Denmark$272.0MDeveloping first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
- Website
Enterome60BiotechnologyParis, France$123.9MClinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
- Website
Infinimmune60BiotechnologyAlameda, United States$75.0MDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
- Website
Supernus Pharmaceuticals60BiotechnologyRockville, United States$17.5MBiopharmaceutical company developing and commercializing CNS disease treatments.
- Website
CellCentric60BiotechnologyCambridge, United Kingdom$375.0MA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
- CRCreate Medicines60BiotechnologyCambridge, USA$122.0M
Developing in vivo immunotherapies for autoimmune diseases and cancer.
- Website
Celerion59BiotechnologyLincoln, USA$45.0MA global leader in clinical pharmacology and bioanalytical sciences.
Showing the 20 closest matches. See the rest on the TIXiMED profile.
Compare TIXiMED head to head
Side by side on what each one does, what it costs, and what real users report.